Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - desvenlafaxine, quantity: 50 mg - tablet, modified release - excipient ingredients: microcrystalline cellulose; hypromellose; povidone; magnesium stearate; purified talc; citric acid monohydrate; alginic acid; titanium dioxide; macrogol 6000; iron oxide red - for the treatment of major depressive disorder, including the preventiton of relapse. not indicated for paediatric use.

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - desvenlafaxine, quantity: 100 mg - tablet, modified release - excipient ingredients: purified talc; povidone; magnesium stearate; alginic acid; citric acid monohydrate; microcrystalline cellulose; hypromellose; titanium dioxide; macrogol 8000; iron oxide red; iron oxide black - for the treatment of major depressive disorder, including the preventiton of relapse. not indicated for paediatric use.

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - desvenlafaxine, quantity: 100 mg - tablet, modified release - excipient ingredients: povidone; hypromellose; alginic acid; citric acid monohydrate; microcrystalline cellulose; magnesium stearate; purified talc; titanium dioxide; macrogol 8000; iron oxide red; iron oxide black - for the treatment of major depressive disorder, including the preventiton of relapse. not indicated for paediatric use.

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - desvenlafaxine, quantity: 50 mg - tablet, modified release - excipient ingredients: povidone; alginic acid; citric acid monohydrate; magnesium stearate; hypromellose; purified talc; microcrystalline cellulose; titanium dioxide; macrogol 6000; iron oxide red - for the treatment of major depressive disorder, including the preventiton of relapse. not indicated for paediatric use.

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - desvenlafaxine, quantity: 50 mg - tablet, modified release - excipient ingredients: citric acid monohydrate; magnesium stearate; povidone; alginic acid; microcrystalline cellulose; purified talc; hypromellose; titanium dioxide; macrogol 6000; iron oxide red - for the treatment of major depressive disorder, including the preventiton of relapse. not indicated for paediatric use.

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - desvenlafaxine, quantity: 100 mg - tablet, modified release - excipient ingredients: alginic acid; povidone; microcrystalline cellulose; citric acid monohydrate; magnesium stearate; purified talc; hypromellose; titanium dioxide; macrogol 8000; iron oxide red; iron oxide black - for the treatment of major depressive disorder, including the preventiton of relapse. not indicated for paediatric use.

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - paroxetine hydrochloride (unii: 3i3t11ud2s) (paroxetine - unii:41vrh5220h) - paroxetine 12.5 mg - paroxetine hydrochloride extended-release tablets are indicated for the treatment of major depressive disorder. the efficacy of paroxetine hydrochloride extended-release tablets in the treatment of a major depressive episode was established in two 12 week controlled trials of outpatients whose diagnoses corresponded to the dsm-iv category of major depressive disorder (see clinical pharmacology: clinical trials). a major depressive episode (dsm-iv) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed mood or loss of interest or pleasure in nearly all activities, representing a change from previous functioning and includes the presence of at least 5 of the following 9 symptoms during the same 2 week period: depressed mood, markedly diminished interest or pleasure in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impai

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - iron polymaltose 370mg equivalent to iron 100mg - film coated tablet - 100 mg - active: iron polymaltose 370mg equivalent to iron 100mg excipient: crospovidone macrogol 6000 magnesium stearate microcrystalline cellulose opadry maroon oy-s-36413 - treatment of iron deficiency in adults and adolescents where the use of ferrous iron supplements is not tolerated, or otherwise inappropriate. prevention of iron deficiency in adults and adolescents at high risk where the use of ferrous iron supplements is not tolerated, or otherwise inappropriate.

Australia - English - Department of Health (Therapeutic Goods Administration)

polytra pty ltd - oyster shell, quantity: 1.39 g (equivalent: calcium, qty 500 mg); colecalciferol, quantity: 3.12 microgram - tablet, uncoated - excipient ingredients: microcrystalline cellulose; magnesium stearate; alginic acid; maize starch; silicon dioxide; dl-alpha-tocopherol; sucrose; hydrolysed gelatin; hydrogenated soya oil - a source of calcium and vitamin d3 for use when dietary intake is inadequate. calcium and vitamin d3 are beneficial for the growth and maintenance of healthy bones and teeth. calcium supplements may be of assistance in the prevention of osteoporosis.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

actavis uk ltd - alginic acid; magnesium trisilicate; sodium bicarbonate; aluminium hydroxide gel dried - chewable tablet - 200mg ; 40mg ; 70mg ; 80mg